Use of Study Data. Subject to the other provisions of this Agreement, Institution and Principal Investigator shall have the right to use such Study Data for its own internal non- commercial research, teaching and Study subject treatment purposes, and for publications, presentations and public disclosures in accordance with Section 8.0. 9.3 Použití údajů o studii. Při dodržení ostatních ustanovení této smlouvy budou mít zdravotnické zařízení a hlavní zkoušející právo použít tyto údaje o studii pro účely svého interního nekomerčního výzkumu, výuky a léčby subjektů studie, v publikacích a prezentacích a při zveřejnění informací v souladu s odstavcem 8.0.
Use of Study Data. Institution will have the non-exclusive right to use Study Data (i) subject to the non-disclosure obligations set forth in section 4 (Confidentiality) and for internal non-commercial research and educational purposes, and (ii) for preparation of publications in accordance with Section 6 (Publication Rights) of this Agreement.
Use of Study Data. University agrees to comply with all applicable state and federal laws and regulations, including the Health Insurance Portability and Accountability Act of 1996, as codified at 42 U.S.C. § 1320d (“HIPAA”) and any current and future regulations promulgated thereunder. Both parties agree that the use of data generated under this Study shall be governed by the terms and conditions of the Informed Consent and HIPAA authorization forms, which have been or will be approved by University’s IRB. Terms and conditions of this Agreement shall not supersede or modify the use of data terms and conditions listed in the Informed Consent and HIPAA authorization forms. Principal Investigator will ensure that the requirements relating to and obtaining Informed Consent and IRB review and approval are met.
Use of Study Data. (a) Use of a Party’s Own Study Data. Novartis may use and analyze the Novartis Study Data for any purpose without obligation or accounting to Olema, who shall hold the Novartis Study Data in confidence pursuant to this Agreement. Olema may use and analyze Olema Study Data for any purpose without obligation or accounting to Novartis, who shall hold Olema Study Data in confidence pursuant to this Agreement.
Use of Study Data. (a) Use of a Party’s Own Study Data. Each Party may use and analyze its own Study Data for any purpose without obligation or accounting to the other.
(b) Use of Combined Therapy Study Data by BMS. BMS and its Affiliates and (sub)licensees shall have the right to use and analyze the Combined Therapy Study Data (x) in connection with its independent development, commercialization or other exploitation of the BMS Compound (alone or in combination with the Five Prime Compound and/or other pharmaceutical agents (but not with any Third Party’s molecule that is designed to selectively bind CSF1R)) and/or for inclusion in the safety database for the BMS Compound, in each case without the consent of, or any obligation to account to, Five Prime, and (y) to conduct studies with Samples pursuant to Section 8.5. Subject to Section 8.5, the results of all such analyses or uses shall be owned by BMS, including any intellectual property arising out of same, unless the Parties shall have agreed otherwise in writing. BMS, its Affiliates and licensees shall also be entitled to use the Combined Therapy Study Data during and following the Term to (1) make regulatory filings and seek approvals for the BMS Compound, either alone or as part of the Combined Therapy and (2) to promote indications based on, and to disseminate, the Combined Therapy Study Data for the benefit of the BMS Compound, either alone or as part of the Combined Therapy, where permitted by and in accordance with Applicable Law; provided that nothing in the foregoing is intended or shall be construed as granting BMS any right or license, expressly or implicitly: (i) to make, have made, use, sell, offer for sale, or import the Five Prime Compound. Five Prime grants BMS, its Affiliates and licensees a Right of Cross-Reference to the relevant Regulatory Documentation Controlled by Five Prime for the Five Prime Compound or the Combined Therapy for the sole purpose of enabling each of them to exercise its rights under clause (1) of this Section 8.3(b) (other than for use in the Ono Territory), which right shall survive any expiration or termination of this Agreement.
(c) Use of Combined Therapy Study Data by Five Prime. Five Prime, its Affiliates and licensees shall have the right to use and analyze the Combined Therapy Study Data (x) in connection with its independent development, commercialization or other exploitation of the Five Prime Compound (alone or in combination with the BMS Compound and/or other pharmaceut...
Use of Study Data. Site may use Study Data in connection with Study Subject care and for internal, non-commercial research purposes subject to the terms of this Agreement including Section 5 “Publication Rights”.
Use of Study Data. Company shall have the unrestricted right to freely use all Study Data that it receives hereunder in whatever manner it desires, subject to Section 6.1. The process and timing for disclosure of Study Data to Company are described in the Study Data Use and Publication Guidelines attached as Exhibit C (the “Data Guidelines”).
Use of Study Data. (a) EQRx may use and analyze the EQRx Study Data for any purpose without obligation or accounting to TPT, who will hold the EQRx Study Data in confidence pursuant to this Agreement. TPT may use and analyze TPT Study Data for any purpose without obligation or accounting to EQRx, who will hold TPT Study Data in confidence pursuant to this Agreement. Further, EQRx shall have the right to [***].
(b) TPT and its Affiliates and (sub)licensees will have the right to use and analyze the Combined Therapy Study Data in connection with the independent development, commercialization or other exploitation of the TPT Study Drug (alone or in combination with other drugs or other pharmaceutical agents) or for inclusion in the safety database for the TPT Study Drug, in each case without the consent of, or any obligation to account to, EQRx; provided that TPT will not disclose any of the unpublished Combined Therapy Study Data and other documentation prepared specifically for use in connection with the Combined Therapy Clinical Trial to a Third Party in connection with the research, development or commercialization of the TPT Study Drug [***]. The results of all such analyses or uses will be owned by TPT, including any intellectual property arising out of same, unless the Parties will have agreed otherwise in a writing separate from this Agreement. TPT and its Affiliates and (sub)licensees will be entitled to use the Combined Therapy Study Data during and following the Term to (i) make regulatory filings, meet regulatory requirements, and seek approvals for the TPT Study Drug, either alone or as part of the Combined Therapy, (ii) evaluate the safety and efficacy of the Combined Therapy and the TPT Study Drug, and (iii) promote indications based on, and to disseminate, the Combined Therapy Study Data for the benefit of the TPT Study Drug, either alone or as part of the Combined Therapy, where permitted by and in accordance with Applicable Law; provided that nothing in the foregoing is intended or will be construed as granting TPT any right or license, expressly or impliedly, to make, have made, use, sell, offer for sale or import the EQRx Study Drug. EQRx hereby grants TPT, its Affiliates and sublicensees of the TPT Study Drug a Right of Cross-Reference to the relevant EQRx Regulatory Documentation for the EQRx Study Drug for the sole purpose of enabling TPT to exercise its rights under clause (i) of this Section 6.3(c) in the Territory, which right will survive any expirati...
Use of Study Data. Subject to the other provisions of this Agreement, Service Provider shall have the right to use such Study Data for its own internal non- commercial research, teaching and Study subject treatment purposes, and for 9.3 Použití údajů o studii. Při dodržení ostatních ustanovení této smlouvy bude mít poskytovatel služeb právo použít takové údaje o studii pro účely svého interního nekomerčního výzkumu, výuky a léčby subjektů studie, v publikacích publications, presentations and public disclosures in accordance with Section 8.0. a prezentacích a při zveřejnění informací v souladu s článkem 8.0.
Use of Study Data. Corporation acknowledges that Institution owns the Study Data; provided, that Corporation is hereby granted an irrevocable, perpetual royalty-free right to receive and use all Study Data, except for the disclosure of subject-identifying information, for any business purpose it deems appropriate, including, without limitation, for submission to any governmental or regulatory agencies, domestic or foreign. Institution shall promptly disclose to Corporation all Study Data.
